Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques

Keyphrases

• Lung 100%
• Immunogenicity 100%
• Aerosol 100%
• Macaque 100%
• Modified Vaccinia Virus Ankara 100%
• Tuberculosis Vaccine 100%
• Antigen 85B 100%
• Mucosal Immune Response 66%
• Aerosol Vaccine 66%
• Vectored Vaccine 66%
• Immunization Programs 33%
• Immunization 33%
• Antibody Response 33%
• Emerging Infectious Diseases 33%
• Tuberculosis 33%
• Vaccine Strategy 33%
• Systemic Immune Response 33%
• Vaccination Route 33%
• Immunization Strategy 33%
• Immunogenic 33%
• Mode of Delivery 33%
• Vaccination Strategy 33%
• Human Trials 33%
• Mycobacterium Bovis BCG 33%
• Rhesus Macaque 33%
• Nonhuman Primate 33%
• Aerosol Route 33%
• Anti-vector Immunity 33%
• Intradermal Injection 33%
• Poxvirus 33%
• Pulmonary Disease 33%
• Boost Immunization 33%
• Improved Vaccines 33%
• Antigen-specific Immune Response 33%
• High Response 33%
• Compartmentalization 33%
• Intradermal Vaccination 33%
• Respiratory mucosa 33%
• Recombinant MVA 33%
• Murine Studies 33%

Immunology and Microbiology

• Immunogenicity 100%
• Vaccinia Virus 100%
• Macaca 100%
• BCG Vaccine 100%
• Mycobacterium Bovis BCG 66%
• Antibody Response 33%
• Immune Response 33%
• Antigen Specificity 33%
• Rhesus Monkey 33%
• Respiratory Mucosa 33%
• Poxviridae 33%
• Immune System 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunogenicity 100%
• BCG Vaccine 100%
• Macaca 100%
• Vaccinia Virus 100%
• Mycobacterium Bovis BCG 66%
• Clinical Trial 33%
• Lung Disease 33%
• Rhesus Monkey 33%
• Poxviridae 33%
• Diseases 33%